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We investigated if mutations in SCNN1A, SCNN1B, SCNN1G, which code for
the different subunits of the amiloride sensitive epithelial sodium channel (ENaC),
explain disease in patients in whom a mutation cannot be found on both CFTR
genes. While ENaC mutations were not the underlying basic defect in the majority
of these patients (more than 90−95%), evidence was found for an involvement in
disease in some patients, such as p.V114I in SCNN1A. The p.W493R variant in
SCNN1A was found at an increased incidence in the tested patients. We found that
p.W493R-SCNN1A led to a 4-fold increase in ENaC current. Given the ﬁnding
of an incidence of 2% of p.W493R-SCNN1A in the general population, and given
the incidence of CF carriers of 1/30, about 1 in 3000 individuals is expected to
be heterozygous for p.W493R-SCNN1A and a CF-causing CFTR mutation. This,
possible partial penetrant, genotype may be sufﬁcient to cause, or to predispose to,
CF-like disease in some individuals.
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b-defensins 2−6 are antimicrobial peptides which form part of a repeat region that
is polymorphic between individuals and therefore the dosage of these defensin
genes/proteins varies.
We determined the number of repeats in 146 F508del homozygous CF patients
from Belgian, Czech and Italian origin. For each patient group, a higher number
of repeats was found in the group of patients with milder disease (FEV1 >70%)
compared to those with more severe disease (FEV1 <70%) (Student T test, P-values
of 0.0006, 0.03 and 0.019).
Furthermore survivors (older than 30 years of age) had a higher number of repeats
than younger CF patients (10−29 years of age) in different CF populations (Belgian,
Hannover, Verona, Copenhagen and Manchester; Chi square P-values where 0.05,
0.03, 0.11, 0.12 and 0.05).
To evaluate this, we cultured nasal epithelial cells individuals with a low or high
number of repeats. The cells were stimulated with 10 ng TNF-a. DEFB4 expression,
as measured by the extent of transcription, was only upregulated by TNF-a in cells
with a high number of repeats (P-value = 0.015).
We also tested the antimicrobial activity of the epithelial cells. We challenged the
epithelial cells with a laboratory strain (PA01) of Pseudomonas aeruginosa and a
clinical isolate, with or without TNF-a. After 3 h, surviving bacteria were counted.
Cells that were stimulated with TNF-a 12 h prior to the bacterial infection were
more bactericidal when a high number of repeats was present.
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Disease severity in cystic ﬁbrosis (CF) varies greatly among patients, even when
they carry the same CFTR mutation. This might partially be due to environmental
factors, yet sibling studies strongly indicate that genes other than CFTR modify CF
disease outcome.
Syntaxin 1A (STX1A) is a negative regulator of CFTR and other ion channels.
Considering that even severe CFTR mutations do not lead to a complete loss of
CFTR function, we hypothesized that CF disease outcome might be inﬂuenced by
variants of the STX1A gene that either increase or hamper STX1A functionality,
leading to a further reduction or enhancement of the remaining CFTR function by
the regulatory activity of STX1A.
We thus screened for SNPs in the complete coding sequence and the adjacent
intronic regions of the STX1A gene in 62 phenotypically well-characterized patients
being homozygous for the most common CFTR mutation, F508del. Two SNPs
which were in strong linkage disequilibrium were found to be signiﬁcantly asso-
ciated with the lung parameters lung clearance index (LCI) and forced expiratory
fraction (FEF50). In an expanded population (n = 93, all F508del homozygous), p-
values reached 0.002 (LCI) and 0.047 (FEF50) for SNP 1 and 0.004 and 0.006 for
SNP 2, respectively. No association was found in non-F508del CF patients (n = 71),
presumably because the contribution of the CFTR genotype on disease expression
outweighs that of the STX1A genotype.
Based on the assumption that STX1A modiﬁes CFTR function, the two SNPs are
currently genotyped in a population with deﬁned nasal potential difference values.
In addition, the two SNPs are functionally characterized.
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The clinical outcome of CF pulmonary disease varies remarkably even in patients with
the same CFTR genotype. That is why searching for genetic modiﬁers located outside
the CFTR gene is provided.
94 CF patients, F508del mutation homozygotes were included into the project. In order
to consider and compare patients’ condition several clinical parameters were recorded:
chest radiography according to the Schwachmann-Kulczycki score, forced expiratory
volume in one second (FEV1) and microbiological testing. For the purpose of this study
a unique clinical score has been created by clinicians: disease severity status (DSS),
which combines many clinical parameters of each patient and shows the degree of lung
function impairment in different age groups.
To consider the effect of non-CFTR genetic polymorphisms on the clinical course of
lung disease in CF patients we have studied molecular variants of 7 genes: PI , MBL2,
IFNG, GSTT1, GSTM1, PTGS1 and PTGS2.
Analysis of PTGS1 and PTGS2 genes as potential CFTR modiﬁers has been provided
for the ﬁrst time in this study. Results of PTGS2 gene analysis were most informative
and conﬁrmed hypothesis that COX2 protein is a protective modiﬁer of CF severity.
Gene / Molecular defect Variant effect Clinical associations
PI / 1237G>A ↓ gene expression, compromised
AAT acute-phase response
GA: higher FEV1, lower DSS score
MBL2 / −550C>G ↑ gene expression, ↑ protein
production
LH: lower FEV1
MBL2 / any mutation in the
coding region
↓ levels of functional MBP protein A0+00: less P.aeruginosa infections, higher SC
score, lower DSS score
IFNG / +874A>T ↑ protein production TT: higher DSS score
IFNG / +1480 ins. T unknown ins−/ins+: lower DSS score
GSTT1 / null deletion lack of protein production del+/del+: higher SC score, lower DSS score
PTGS1 / 639C>A unknown CA: higher FEV1
PTGS1 / any mutation in
the coding region
destabilization of protein structure AM: more P. aeruginosa infections
PTGS2 / −765G>C ↓ gene expression GC: higher FEV1
PTGS2 / 8473T>C degradation of PTGS2 mRNA, ↓
protein concentration
TC: higher FEV1, less P. aeruginosa infections,
higher SC score, lower DSS score
